Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Key Respiratory Syncytial Virus Infection Pipeline therapies such as RSV-F, V-306, CodaVax-RSV, mRNA-1345, MV-012-968, RV521, BARS13, EDP-938, MEDI8897, RSV MAT, RSVpreF, JNJ-53718678, RSV vaccine ...

Palivizumab, when given through the veins or into a muscle (systemically), reduces hospitalisations due to respiratory syncytial virus (RSV) and reduces respiratory problems later on (chest wheezing), ...

Respiratory syncytial virus (RSV) is a common germ that can settle into your lungs and airways. It's the top cause of upper respiratory infection in babies and toddlers, but anyone can get it.

Newark, New Castle, USA, June 21, 2023 (GLOBE NEWSWIRE) -- A recent report by Growth Plus Reports estimated the global respiratory syncytial virus (RSV) therapeutics market to be worth US$ 1.84 ...

The AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial is a randomized, placebo-controlled, observer-blind, multi-country trial to demonstrate the efficacy of a single dose of GSK's ...

Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, ...

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections. RSV infection is usually mild and self-limiting but symptoms may be severe in young children, the elderly ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...

Electron microscope shows human respiratory syncytial virus (RSV) virions, colourised blue, and anti-RSV F protein/gold antibodies, colourised yellow, shedding from the surface of human lung cells ...